Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results

Protagonist announced Phase IIb data for an oral IL-23R antagonist partnered with J&J • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D